Breast Cancer | Standard or Hypofractionated Radiotherapy Versus Accelerated Partial Breast Irradiation (APBI)for Breast Cancer

Breast Cancer research study

What is the primary objective of this study?

The standard treatment for localized breast cancer is based on conservative surgery (when possible) followed by radiation therapy (RT) delivered to the whole breast. The recommended total RT dose is 45 to 50 Gy delivered in 4.5 to 5 weeks followed by a 10 to 16 Gy boost to the tumor bed for 1 to 1.5 weeks. The rationale for the development of APBI was based on the difficulty for many patients to reach RT centers to receive standard whole breast irradiation (WBI) after conservative surgery. APBI offers decreased overall treatment time and several theoretical advantages over WBI, including a decrease in dose delivered to uninvolved portions of the breast and adjacent organs. If equivalence between the two treatments can be shown, then APBI will be considered as a historic evolution in breast cancer management. In this phase III trial, designed in postmenopausal women > 50 years of age, the objective is to compare the effectiveness and safety of APBI compared with whole breast irradiation. This study is also designed to ensure high quality criteria for surgery, pathology and RT techniques in the 3 arms and will allow to provide data on economics and costs.

Who is eligible to participate?

Inclusion Criteria: - Women aged ≥ 50 years - Menopausal status confirmed - Pathology confirmation of invasive carcinoma (all types) - Complete tumor removal and conservative surgery - Pathologic tumor size of invasive carcinoma ≤ 2cm (including the in situ component) pT1 - All histopathologic grades - Clear lateral margins for the invasive and in situ disease (> 2mm) - pN0 or pN(i+) - No metastasis - Radiotherapy should be started more than 4 weeks and less than 12 weeks after last surgery - Surgical clips (4 to 5 clips in the tumor bed) - No prior breast or mediastinal radiotherapy - ECOG 0-1 - Information to the patient and signed informed consent Exclusion Criteria: - Multifocal invasive ductal carcinoma defined as the presence of at least two distinct tumors that are separated by normal tissue or when the distance between the two lesions does not permit conservative surgery - Bilateral breast cancer - No or less than 4 surgical clips in the tumor bed - Nodal involvement : pN1 (including micrometastasis, mi+), pN2, pN3 - Metastatic disease - internal mammary node involvement or supraclavicular lymph node involvement - Indication of chemotherapy or trastuzumab - Involved or close lateral margins for the invasive and /or in situ components (< 2mm) AND impossibility to re-operate or impossible to perform another conservative surgery - Patients with known BRCA1 or BRCA2 mutations - Previous mammoplasty - Previous homolateral breast and/or mediastinal irradiation - Previous invasive cancer (except basocellular epithelioma or in situ carcinoma of the cervix) - No geographical, social or psychologic reasons that would prevent study follow

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Breast Cancer


Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Radiation:Whole Breast Irradiation + Boost or Hypofractionated irradiationWhole Breast Irradiation 50Gy + Boost 16 Gy or Whole breast, either 40Gy in 15 fractions in 3 weeks or 42,5Gy in 16 fractions in 3 weeks

Radiation:Accelerated partial breast irradiationTumor bed 40Gy in 10 fractions, 2 fractions of 4Gy per day in 5 to 7 days.

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Standard or Hypofractionated radiotherapyWhole breast RT, 50Gy + "boost" 16Gy. Whole breast hypofractionated RT without boost, either 40Gy or 42,5Gy.

Accelerated Partial Breast Irradiation (APBI)APBI using 3D CRT technique, in 5 days, 38.5 Gy to the tumor bed .

Study Status

Active, not recruiting

Start Date: December 2010

Completed Date: October 2025

Phase: Phase 3

Type: Interventional


Primary Outcome: rate of local recurrence

Secondary Outcome: Ipsilateral breast recurrence-free survival

Study sponsors, principal investigator, and references

Principal Investigator: Yazid Belkacemi, MD PhD

Lead Sponsor: UNICANCER


More information:

Discuss Breast